Tairx, Inc.
Clinical trials sponsored by Tairx, Inc., explained in plain language.
-
New hope for advanced liver cancer: drug combo trial opens
Disease control Recruiting nowThis study tests a new experimental drug called CVM-1118 combined with the immunotherapy nivolumab in people with advanced liver cancer that cannot be surgically removed. The goal is to see if the combination shrinks tumors or slows cancer growth. About 95 adults aged 18 and olde…
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New triple therapy shows promise for tough liver cancers
Disease control Recruiting nowThis study tests a combination of an experimental drug (CVM-1118), an immunotherapy (sintilimab), and a procedure that blocks the tumor's blood supply (TACE) in people with liver cancer that cannot be cured but hasn't spread. About 40 adults will receive all three treatments to s…
Phase: PHASE2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New gel targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests an oral gel called TRX-920 in people with advanced solid tumors that no longer respond to standard treatments. The gel contains a chemotherapy drug that aims to shrink tumors with fewer side effects than the standard IV version. About 30 participants …
Phase: PHASE1 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC